ES2178268T3 - Formulaciones de liberacion controlada. - Google Patents

Formulaciones de liberacion controlada.

Info

Publication number
ES2178268T3
ES2178268T3 ES98950189T ES98950189T ES2178268T3 ES 2178268 T3 ES2178268 T3 ES 2178268T3 ES 98950189 T ES98950189 T ES 98950189T ES 98950189 T ES98950189 T ES 98950189T ES 2178268 T3 ES2178268 T3 ES 2178268T3
Authority
ES
Spain
Prior art keywords
film
active material
water
forming polymer
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98950189T
Other languages
English (en)
Inventor
John Michael Newton
Lee Fung Siew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Application granted granted Critical
Publication of ES2178268T3 publication Critical patent/ES2178268T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Abstract

Un procedimiento para producir un compuesto de liberación retardada que contiene un material activo o una forma de dosificación que contiene un material activo y una película formada a partir de una composición formadora de película que consiste en una mezcla de un polímero formador de película substancialmente insoluble en agua y amilosa, incluyendo el procedimiento el contacto del material activo o de la forma de dosificación que contiene el material activo con una solución de la composición formadora de película en un sistema de disolventes que incluye (1) agua y un (2) disolvente orgánico miscible en agua que por si mismo es capaz de disolver el polímero formador de película y eliminar el disolvente, en donde la relación de peso entre amilosa y polímero formador de película está en el intervalo de 1:2 a 3:2 y el sistema de disolventes contiene al menos un 50% de disolvente orgánico.
ES98950189T 1997-10-23 1998-10-23 Formulaciones de liberacion controlada. Expired - Lifetime ES2178268T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9722426.5A GB9722426D0 (en) 1997-10-23 1997-10-23 Controlled release formulations

Publications (1)

Publication Number Publication Date
ES2178268T3 true ES2178268T3 (es) 2002-12-16

Family

ID=10820995

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98950189T Expired - Lifetime ES2178268T3 (es) 1997-10-23 1998-10-23 Formulaciones de liberacion controlada.

Country Status (10)

Country Link
US (1) US6534549B1 (es)
EP (1) EP1024795B1 (es)
JP (2) JP2001520986A (es)
AT (1) ATE221773T1 (es)
CA (1) CA2302585C (es)
DE (1) DE69807104T2 (es)
DK (1) DK1024795T3 (es)
ES (1) ES2178268T3 (es)
GB (1) GB9722426D0 (es)
WO (1) WO1999021536A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6929884B2 (en) * 2001-04-19 2005-08-16 Zinc Matrix Power, Inc. Method for manufacture of films containing insoluble solids embedded in cellulose-based films
US8282955B2 (en) 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
GB0203421D0 (en) * 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
WO2004093883A2 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
FR2862654B1 (fr) * 2003-11-20 2006-02-10 Roquette Freres Composition amylacee filmogene
EP1547601A1 (en) 2003-12-23 2005-06-29 Ferring B.V. Coating method
WO2005097061A1 (en) * 2004-04-01 2005-10-20 Procyte Corporation Encapsulated peptide copper complexes and compositions and methods related thereto
US8048919B2 (en) * 2004-06-28 2011-11-01 Archer Daniels Midland Company Use of ethyl lactate as an excipient for pharmaceutical compositions
US7384916B2 (en) * 2005-03-16 2008-06-10 Procyte Corporation Methods and compositions for preventing and treating aging or photodamaged skin
US20090017110A1 (en) * 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP2009544684A (ja) * 2006-07-27 2009-12-17 ユニヴァーシティ・オヴ・サンダーランド デンプンを含むコーティング組成物
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
DK2272119T3 (da) 2008-03-27 2014-07-07 Zpower Llc Elektrodeseparator
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
FR2934467B1 (fr) * 2008-07-31 2014-08-22 Roquette Freres Forme solide pelliculee et procede de pelliculage a temperature ambiante.
EP2179727B1 (en) * 2008-10-27 2013-05-29 Roquette Freres Water insoluble polymer: modified starch derivative-based film coatings for colon targeting
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
MX2011007393A (es) 2009-01-12 2011-10-06 Biokier Inc Composicion y metodo para el tratamiento de la diabetes.
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9301938B2 (en) 2009-09-23 2016-04-05 Biokier, Inc. Composition and method for treatment of diabetes
EP2845595A1 (en) 2009-10-01 2015-03-11 Aptalis Pharmatech, Inc. Orally administered corticosteriod compositions
US9963368B2 (en) 2010-11-15 2018-05-08 Archer Daniels Midland Company Microemulsions and uses thereof in dispersing catalysts
LT2659881T (lt) 2012-04-30 2018-02-12 Tillotts Pharma Ag Uždelsto atpalaidavimo vaisto forma
US20140271931A1 (en) * 2013-03-12 2014-09-18 Perosphere Inc. Anti-Acne Topical Films
NZ717159A (en) 2013-10-29 2019-06-28 Tillotts Pharma Ag A delayed release drug formulation
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662900A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662902A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations

Also Published As

Publication number Publication date
DE69807104D1 (de) 2002-09-12
GB9722426D0 (en) 1997-12-24
WO1999021536A1 (en) 1999-05-06
CA2302585A1 (en) 1999-05-06
US6534549B1 (en) 2003-03-18
EP1024795B1 (en) 2002-08-07
EP1024795A1 (en) 2000-08-09
JP2001520986A (ja) 2001-11-06
DK1024795T3 (da) 2002-12-02
DE69807104T2 (de) 2002-12-05
JP2010270335A (ja) 2010-12-02
CA2302585C (en) 2007-09-25
ATE221773T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
ES2178268T3 (es) Formulaciones de liberacion controlada.
PE20001049A1 (es) Complejos estables de compuestos escasamente solubles
KR870700344A (ko) 유효 화합물을 서서히 방출하는 신규 약제, 그의 제조방법 및 이신규 제제물의 용도
AR009127A1 (es) Procedimiento de preparacion de nanoparticulas de metilideno malona, particulas que contienen eventualmente una o mas moleculas biologicamente activas y composiciones farmaceuticas que las contienen
BR9814729A (pt) Método e composição de uma preparação oral de itraconazol
AR038880A1 (es) Composiciones farmaceuticas en granulos de liberacion inmediata y un proceso continuo para prepararlas
CO5440227A1 (es) Composicion antihelmitica e inyectable mejorada de crecimiento
KR950007850A (ko) 항균물질 및 항궤양물질 포함 제제
BR0116377A (pt) Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria
AR012820A1 (es) Un proceso para la preparacion de microparticulas biodegradables y biocompatibles
ES2118677T1 (es) Una composicion que comprende un agente activo disuelto en un vehiculo vitrificante y un procedimiento para su preparacion.
ES2063249T3 (es) Procedimiento para preparar composiciones de detergente de alta densidad aparente.
ES2186197T3 (es) Procedimiento de solubilizacion de principios farmaceuticamente activos en agua y en vehiculos acuosos.
AR033946A1 (es) Un sistema terapeutico transdermal que comprende microreservorios y un procedimiento para la manufactura de sistemas de microreservorios basados en polisiloxanos y solventes ambifilos.
KR880004803A (ko) 분무 건조된 아세트아미노펜
JP2002508431A5 (es)
ATE230274T1 (de) Physiologisch aktives polypeptid enthaltende zubereitung mit verzögerter freisetzung und deren herstellung
DK1212039T3 (da) Sammensætning til inhalation omfattende delta-9-tetrahydrocannabinol i et semivandigt oplösningsmiddel
UY25800A1 (es) Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.
PE103799A1 (es) Procedimiento de purificacion de mesilato de alatrofloxacino
AR024959A1 (es) Una composicion farmaceutica liquida basada en paracetamol
BR9406414A (pt) Composições na forma de soluções sólidas processo para preparar as mesmas aplicação das mesmas e pós granulados tabletes pelotas supositórios e soluções injetáveis a partir das mesmas
JPS51136622A (en) Process for preparation of isocyanic acid derivatives
ES2071642T3 (es) Composiciones detergentes liquidas.
ES2120722T3 (es) Composicion y proceso para reducir o prevenir la contaminacion con metales y acidos en el drenaje de las rocas.